First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations-Reference-Cited by-同舟云学术

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Published:2023-02 Issue:2 Volume:18 Page:204-222
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Paz-Ares Luis G.,Ciuleanu Tudor-Eliade,Cobo Manuel,Bennouna Jaafar,Schenker Michael,Cheng Ying,Juan-Vidal Oscar,Mizutani Hideaki,Lingua Alejo,Reyes-Cosmelli Felipe,Reinmuth Niels,Menezes Juliana,Jassem Jacek,Protsenko Svetlana,Richardet Eduardo,Felip Enriqueta,Feeney Kynan,Zurawski Bogdan,Alexandru Aurelia,de la Mora Jimenez Emmanuel,Dakhil Shaker,Lu Shun,Reck Martin,John Thomas,Hu Nan,Zhang Xiaoqing,Sylvester Judi,Eccles Laura J.,Grootendorst Diederik J.,Balli David,Neely Jaclyn,Carbone David P.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference50 articles.

1. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer;Hellmann;N Engl J Med,2019

2. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019

3. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC;Herbst;N Engl J Med,2020

4. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial;Paz-Ares;Lancet Oncol,2021

5. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50;Reck;J Clin Oncol,2021

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape;Cancer Treatment Reviews;2024-11

2. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial;European Journal of Cancer;2024-11

3. Brain Metastases as Inaugural Sign of Non-Small Cell Lung Carcinoma: Case Series and Review of Literature;Cancers;2024-09-08

4. „Kelch-like ECH-associated protein 1“ (KEAP1);Trillium Krebsmedizin;2024-08-06

5. Efficacy of first‐line immune checkpoint inhibitor and anti‐angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen‐mutant advanced non‐small‐cell lung cancer: a systematic review and network meta‐analysis;Thoracic Cancer;2024-07-31